Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Blood Platelets | 13 | 2026 | 379 | 5.780 |
Why?
|
| Blood Preservation | 10 | 2025 | 346 | 4.130 |
Why?
|
| Hemostatics | 5 | 2023 | 64 | 3.500 |
Why?
|
| Platelet Transfusion | 6 | 2026 | 77 | 2.950 |
Why?
|
| Hemostasis | 6 | 2024 | 98 | 2.120 |
Why?
|
| Blood Donors | 4 | 2026 | 144 | 1.800 |
Why?
|
| Platelet Aggregation | 3 | 2025 | 99 | 1.610 |
Why?
|
| Blood Safety | 2 | 2021 | 11 | 1.260 |
Why?
|
| Hemorrhage | 7 | 2025 | 822 | 1.100 |
Why?
|
| Thrombin | 3 | 2023 | 172 | 1.040 |
Why?
|
| Wounds and Injuries | 6 | 2024 | 961 | 0.910 |
Why?
|
| Cryopreservation | 1 | 2025 | 113 | 0.840 |
Why?
|
| Microfluidics | 1 | 2024 | 61 | 0.810 |
Why?
|
| Fibrinogen | 2 | 2024 | 180 | 0.810 |
Why?
|
| Testosterone | 2 | 2024 | 416 | 0.790 |
Why?
|
| Hormone Replacement Therapy | 1 | 2024 | 107 | 0.780 |
Why?
|
| Precision Medicine | 2 | 2025 | 459 | 0.700 |
Why?
|
| Factor VIII | 1 | 2021 | 106 | 0.640 |
Why?
|
| Leukocyte Reduction Procedures | 1 | 2019 | 29 | 0.580 |
Why?
|
| Blood Transfusion | 5 | 2023 | 409 | 0.520 |
Why?
|
| Cold Temperature | 4 | 2025 | 206 | 0.470 |
Why?
|
| Resuscitation | 3 | 2023 | 310 | 0.410 |
Why?
|
| Blood Coagulation Disorders | 2 | 2024 | 198 | 0.320 |
Why?
|
| Tranexamic Acid | 2 | 2022 | 59 | 0.320 |
Why?
|
| Humans | 26 | 2026 | 145474 | 0.280 |
Why?
|
| Plasma | 2 | 2021 | 223 | 0.280 |
Why?
|
| Erythrocytes | 2 | 2024 | 748 | 0.230 |
Why?
|
| Plateletpheresis | 2 | 2023 | 28 | 0.230 |
Why?
|
| Erythrocyte Transfusion | 2 | 2026 | 225 | 0.230 |
Why?
|
| Bleeding Time | 1 | 2024 | 5 | 0.210 |
Why?
|
| Erythrocyte Deformability | 1 | 2024 | 23 | 0.210 |
Why?
|
| von Willebrand Factor | 1 | 2024 | 85 | 0.200 |
Why?
|
| Purines | 1 | 2023 | 187 | 0.180 |
Why?
|
| Animals | 8 | 2025 | 38030 | 0.180 |
Why?
|
| Cell Count | 1 | 2023 | 319 | 0.180 |
Why?
|
| Blood Coagulation Tests | 1 | 2022 | 72 | 0.180 |
Why?
|
| Cell Separation | 1 | 2023 | 305 | 0.180 |
Why?
|
| Antifibrinolytic Agents | 1 | 2022 | 64 | 0.170 |
Why?
|
| Sterilization | 1 | 2021 | 24 | 0.170 |
Why?
|
| Thromboembolism | 1 | 2022 | 129 | 0.170 |
Why?
|
| Heparin | 1 | 2022 | 247 | 0.160 |
Why?
|
| Central Venous Catheters | 1 | 2021 | 53 | 0.160 |
Why?
|
| Blood Coagulation Factors | 1 | 2021 | 71 | 0.160 |
Why?
|
| Enoxaparin | 1 | 2021 | 68 | 0.160 |
Why?
|
| Male | 10 | 2026 | 72842 | 0.160 |
Why?
|
| Shock | 1 | 2021 | 110 | 0.150 |
Why?
|
| Lymphoid Tissue | 1 | 2020 | 78 | 0.150 |
Why?
|
| Blood Component Transfusion | 1 | 2020 | 102 | 0.150 |
Why?
|
| Catheterization, Central Venous | 1 | 2021 | 123 | 0.150 |
Why?
|
| Free Radical Scavengers | 1 | 2019 | 82 | 0.140 |
Why?
|
| Female | 9 | 2026 | 78844 | 0.140 |
Why?
|
| Critical Illness | 2 | 2022 | 900 | 0.140 |
Why?
|
| Venous Thrombosis | 1 | 2021 | 196 | 0.140 |
Why?
|
| Vasoconstrictor Agents | 1 | 2019 | 150 | 0.140 |
Why?
|
| Cell-Derived Microparticles | 1 | 2019 | 73 | 0.130 |
Why?
|
| Thrombelastography | 1 | 2019 | 192 | 0.130 |
Why?
|
| Complement Pathway, Classical | 1 | 2017 | 17 | 0.130 |
Why?
|
| HLA-A Antigens | 1 | 2017 | 52 | 0.130 |
Why?
|
| Oxidative Stress | 1 | 2024 | 1356 | 0.130 |
Why?
|
| Tuberculosis | 1 | 2020 | 283 | 0.120 |
Why?
|
| Shock, Hemorrhagic | 1 | 2019 | 199 | 0.120 |
Why?
|
| Case-Control Studies | 1 | 2024 | 3623 | 0.120 |
Why?
|
| Adult | 6 | 2026 | 40777 | 0.120 |
Why?
|
| Complement Inactivating Agents | 1 | 2017 | 74 | 0.120 |
Why?
|
| Metabolome | 1 | 2019 | 388 | 0.120 |
Why?
|
| Aorta | 1 | 2019 | 440 | 0.120 |
Why?
|
| Phenotype | 1 | 2024 | 3155 | 0.120 |
Why?
|
| Cell Adhesion | 1 | 2017 | 451 | 0.120 |
Why?
|
| Anticoagulants | 1 | 2021 | 748 | 0.110 |
Why?
|
| Middle Aged | 4 | 2026 | 36215 | 0.110 |
Why?
|
| Endothelial Cells | 2 | 2019 | 874 | 0.110 |
Why?
|
| Monocytes | 1 | 2017 | 539 | 0.100 |
Why?
|
| Metabolomics | 1 | 2019 | 732 | 0.100 |
Why?
|
| Prospective Studies | 2 | 2022 | 8057 | 0.090 |
Why?
|
| Immunosuppressive Agents | 1 | 2017 | 838 | 0.090 |
Why?
|
| Double-Blind Method | 3 | 2022 | 2062 | 0.090 |
Why?
|
| ABO Blood-Group System | 2 | 2023 | 58 | 0.090 |
Why?
|
| Child, Preschool | 2 | 2022 | 11853 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 1505 | 0.080 |
Why?
|
| Proportional Hazards Models | 2 | 2023 | 1327 | 0.070 |
Why?
|
| Child | 3 | 2022 | 22707 | 0.060 |
Why?
|
| Lung | 1 | 2020 | 4106 | 0.060 |
Why?
|
| Platelet Count | 1 | 2026 | 94 | 0.060 |
Why?
|
| Adolescent | 2 | 2022 | 22529 | 0.060 |
Why?
|
| Logistic Models | 2 | 2020 | 2134 | 0.050 |
Why?
|
| Hemolysis | 1 | 2024 | 242 | 0.050 |
Why?
|
| Cell Survival | 1 | 2024 | 1100 | 0.040 |
Why?
|
| L-Selectin | 1 | 2020 | 27 | 0.040 |
Why?
|
| Endothelium | 1 | 2021 | 119 | 0.040 |
Why?
|
| Trehalose | 1 | 2020 | 35 | 0.040 |
Why?
|
| Citric Acid Cycle | 1 | 2019 | 58 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2020 | 172 | 0.040 |
Why?
|
| Macaca mulatta | 1 | 2020 | 186 | 0.040 |
Why?
|
| Tissue Preservation | 1 | 2019 | 11 | 0.040 |
Why?
|
| Myeloid Cells | 1 | 2020 | 147 | 0.040 |
Why?
|
| Hematologic Diseases | 1 | 2019 | 66 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2021 | 782 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2021 | 420 | 0.040 |
Why?
|
| Standard of Care | 1 | 2019 | 81 | 0.040 |
Why?
|
| Arginine | 1 | 2019 | 264 | 0.030 |
Why?
|
| Trauma Severity Indices | 1 | 2018 | 115 | 0.030 |
Why?
|
| Rabbits | 1 | 2019 | 652 | 0.030 |
Why?
|
| Leukocytes | 1 | 2019 | 296 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2019 | 592 | 0.030 |
Why?
|
| P-Selectin | 1 | 2017 | 29 | 0.030 |
Why?
|
| Macrophage-1 Antigen | 1 | 2017 | 26 | 0.030 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2021 | 269 | 0.030 |
Why?
|
| Complement C5a | 1 | 2017 | 54 | 0.030 |
Why?
|
| Complement C3a | 1 | 2017 | 40 | 0.030 |
Why?
|
| Cell Communication | 1 | 2019 | 328 | 0.030 |
Why?
|
| Exocytosis | 1 | 2017 | 85 | 0.030 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2020 | 318 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2017 | 247 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2019 | 730 | 0.030 |
Why?
|
| ROC Curve | 1 | 2018 | 617 | 0.030 |
Why?
|
| Temperature | 1 | 2019 | 633 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2020 | 776 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2020 | 1038 | 0.030 |
Why?
|
| Survival Rate | 1 | 2020 | 2090 | 0.030 |
Why?
|
| Disease Management | 1 | 2019 | 653 | 0.030 |
Why?
|
| Neutrophils | 1 | 2020 | 1124 | 0.030 |
Why?
|
| Cell Line | 1 | 2020 | 2823 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2019 | 892 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2020 | 1131 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 2028 | 0.020 |
Why?
|
| Cytokines | 1 | 2020 | 2067 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 2930 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2026 | 11772 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2017 | 4148 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 5983 | 0.020 |
Why?
|
| Mice | 1 | 2024 | 18329 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2024 | 17291 | 0.010 |
Why?
|
| Aged | 1 | 2024 | 26153 | 0.010 |
Why?
|
| Neoplasms | 1 | 2019 | 2906 | 0.010 |
Why?
|
| Young Adult | 1 | 2020 | 14218 | 0.010 |
Why?
|